Sherko Kümmel

Prof. Dr. Sherko Kümmel

Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany;Klinik für Gynäkologie mit Brustzentrum, Charité-Universitätsmedizin Berlin, Berlin, Germany;West German Study Group, Moenchengladbach, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GDGustav J Dobos
Gustav J Dobos
PVPetra Voiss
Petra Voiss
ISIlka Schwidde
Ilka Schwidde
Kyung-Eun (Anna) ChoiKyung-Eun (Anna) Choi
Kyung-Eun (Anna) Choi
APAnna Paul
Anna Paul
Sherko KümmelSherko Kümmel
Sherko Kümmel
Malignant breast neoplasms are among the most frequent forms of cancer in the Western world. Conventional treatment of breast cancer may include surgery, hormonal therapy, chemotherapy, radiation and/or immunotherapy, all of which are often accompanied by severe side effects. Complementary and alternative medicine (CAM) treatments have been shown to be effective in alleviating those symptoms. Furthermore, with patient survival rates increasing, oncologists, psychologists and other therapists have to become more sensitive to the needs of cancer survivors that go beyond than the mere alleviation of symptoms. Many CAM methods are geared to treat the patient in a holistic manner and thus are also concerned with the patient’s psychological and spiritual needs.


5 February 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Peter FaschingPeter Fasching
Peter Fasching
SJSebastian M. Jud
Sebastian M. Jud
MHMaik Hauschild
Maik Hauschild
Sherko KümmelSherko Kümmel
Sherko Kümmel
MSMartin Schütte
Martin Schütte
MLMichael Patrick Lux
Michael Patrick Lux
The objective of this prospectively randomized phase II trial (Trial registration: EUCTR2004-004007-37-DE) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone (LET) or letrozole and zoledronic acid (LET + ZOL). Patients were randomly assigned to receive either LET 2.5 mg/day (n = 79) or the combination of LET 2.5 mg/day and a total of seven infusions of ZOL 4 mg every 4 weeks (n = 89) for 6 months. Primary endpoint was clinical response rate as assessed by mammogram readings. The study was terminated prematurely due to insufficient recruitment. We report here on an exploratory analysis of this data. Central assessment of tumor sizes during the treatment period was available for 131 patients (66 LET, 65 LET + ZOL). Clinical responses (complete or partial) were seen in 54.5% (95% CI: 41.8-66.9) of the patients in the LET arm and 69.2% (95% CI: 56.6-80.1) of those in the LET + ZOL arm (P = 0.106). A multivariate model showed an OR of 1.72 (95% CI: 0.83-3.59) for the experimental arm. No increase in the clinical response rate was observed with the addition of ZOL to a neoadjuvant treatment regimen with LET. However a trend towards a better reponse in the LET + ZOL arm could be observed. This trend is consistent with previous studies that have investigated the addition of ZOL to chemotherapy, and it may support the evidence for a direct antitumor action of zoledronic acid.

1 October 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
Sherko KümmelSherko Kümmel
Sherko Kümmel
SPStefan Paepke
Stefan Paepke
JHJens Huober
Jens Huober
CSChristian Schem
Christian Schem
MUMichael Untch
Michael Untch
SLSibylle Loibl
Sibylle Loibl

21 June 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MWMarkus Wallwiener
Markus Wallwiener
Naiba NabievaNaiba Nabieva
Naiba Nabieva
MFManuel Feisst
Manuel Feisst
TFTanja Fehm
Tanja Fehm
JWJohann de Waal
Johann de Waal
Peter FaschingPeter Fasching
Peter Fasching
Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim of this study was to analyze persistence of palliative aromatase inhibitor (AI) monotherapy in MBC patients. EvAluate-TM is a prospective, multicenter, noninterventional study to evaluate treatment with letrozole in postmenopausal women with hormone receptor–positive breast cancer. To assess therapy persistence, defined as the time from therapy start to the end of the therapy (TTEOT), two pre-specified study visits took place after 6 and 12 months. Competing risk survival analyses were performed to identify patient and tumor characteristics that predict TTEOT. Out of 200 patients, 66 patients terminated treatment prematurely, 26 (13%) of them due to causes other than disease progression. Persistence rate for reasons other than progression at 12 months was 77.7%. Persistence was lower in patients who reported any adverse event (AE) in the first 30 days of ET (89.5% with no AE and 56% with AE). Furthermore, patients had a lower persistence if they reported compliance problems in the past before letrozole treatment. Despite suffering from a life-threatening disease, AEs of an AI will result in a relevant number of treatment terminations that are not related to progression. Some subgroups of patients have very low persistence rates. Especially with regard to novel endocrine combination therapies, these data imply that some groups of patients will need special attention to guide them through the therapy process. Clinical Trials Number: CFEM345DDE19

15 October 2014 in Health Care Management Science
Verified
Journal Article
Closed access
PDF file
ASAlexander Scherrer
Alexander Scherrer
ISIlka Schwidde
Ilka Schwidde
ADAndreas Dinges
Andreas Dinges
PRPatrick Rüdiger
Patrick Rüdiger
Sherko KümmelSherko Kümmel
Sherko Kümmel
KKKarl-Heinz Küfer
Karl-Heinz Küfer